ADHD

At the 2022 Pediatric Academic Societies meeting, Shruti Mittal, MD, FAAP, looked at how many children with attention-deficit/hyperactivity disorder get started on behavioral therapy before medication in the preschool years.

At the 43rd National Conference on Pediatric Health Care for nurse practitioners in Dallas, Texas, a look at the newest medications for children with attention-deficit/hyperactivity disorder.

Catch up on all the latest in ADHD from the The American Professional Society of ADHD (attention-deficit/hyperactivity disorder) and Related Disorders (APSARD) virtual 2022 Annual Meeting.

In a clinical study of healthy adults, Dyanavel XR tablets were deemed to be bioequivalent to amphetamine extended-release oral suspension in patients with attention-deficit/hyperactivity disorder (ADHD) by the US Food and Drug Administration (FDA).

At the virtual 2021 American Academy of Pediatrics National Conference & Exhibition, Grace Wang, MD, FAAP, discusses how treatment of underlying sleep disorders can improve ADHD symptomatology.

A study has found that prenatal analgesic opioid exposure of 5 or more weeks is associated with a slightly elevated risk of attention-deficit/hyperactivity disorder (ADHD) in children compared to exposure of 4 weeks or less.

AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is available for prescription to help provide rapid and extended duration of attention-deficit/hyperactivity disorder (ADHD) symptoms.

A study examines the effect of after-school activity participation on a child's attention-deficit/hyperactivity disorder (ADHD) severity.

Stimulants are recommended as the first-line treatment for attention-deficit/hyperactivity disorder (ADHD). A study examines whether α2-adrenergic agonists could be effective as well.

A study examines if promoting positive behaviors including masking leads to improved face covering in children with autism spectrum disorder and/or attention-deficit/hyperactivity disorder.

The US Food and Drug Administration (FDA) approves first novel non-stimulant medication to treat attention-deficit/hyperactivity disorder (ADHD) in children in a decade.

Unfortunately, disparities in health care are nothing unusual. A report examines if there are disparities in attention-deficit/hyperactivity disorder (ADHD) diagnosis and treatment due to race and ethnicity.

A new study examines whether maternal autoimmune diseases are linked to attention-deficit/hyperactivity disorder (ADHD).

A presentation at the virtual 2020 American Academy of Pediatrics National Conference & Exhibition reminded practitioners of the 3 guiding principles of psychopharmacology.

COVID-19 has created many stresses: mental, job-related, and health. For some caregivers, these stressors are complicated further with caring for a child with attention-deficit/hyperactive disorder (ADHD).

More than 1 condition can have an impact on health outcomes. A new investigation examines how multimorbidity can impact educational outcomes.

Attention-deficit/hyperactivity disorder (ADHD) was first recognized over 100 years ago, but the diagnostic criteria has changed over the years. Here's a look at the latest guidance for diagnosing ADHD.

Following the diagnosis of attention-deficit/hyperactivity disorder (ADHD), the next step is treatment, which can include parent behavior management training, school-based interventions, and medication. Here's a look at the latest in ADHD treatments.

Research has indicated that prenatal exposure to acetaminophen has an impact on attention-deficit/hyperactivity disorder (ADHD). An investigation offers even more evidence.

Attention-deficit/hyperactivity disorder (ADHD) is marked by age-inappropriate levels of inattention and activity. A report from Finland examines how relative immaturity in the first years of school could increase the risk of ADHD medication use.

Endocrine-disrupting chemicals are nearly ubiquitous in day-to-day life. Could they be linked to attention-deficit/hyperactivity disorder-like (ADHD) behavior?

Severe iodine deficiency in pregnancy has been linked to intellectual disabilities in offspring. An investigation studies whether the same is true for mild-to-moderate deficiency.

Tics and attention-deficit/hyperactivity disorder can co-occur. A presentation at the 2020 Virtual Conference on Pediatric Health Care offers guidance.

The US Food and Drug Administration (FDA) permitted marketing for the EndeavorRx, a game-based digital device meant to improve attention function in patients with attention-deficit/hyperactivity disorder (ADHD).

Teenagers with attention-deficit/hyperactivity disorder (ADHD) or parent-reported “trouble staying focused” are poorer drivers and make more driving errors than their peers during the teenagers’ learning permit period according to recent survey data.